Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting

Tumori

Volumn 94, Issue 4, 2008, Pages 447-452

  Celio, Luigi ^a   Denaro, Angela ^a   Canova, Stefania ^a   Gevorgyan, Arpine ^a   Bajetta, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antagonist; Antiemetics; Chemotherapy induced nausea and vomiting; Palonosetron

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; BLEOMYCIN; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOLASETRON MESILATE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANISETRON; OLANZAPINE; ONDANSETRON; OXALIPLATIN; PALONOSETRON; SEROTONIN 3 ANTAGONIST;

ADJUVANT THERAPY; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERGLYCEMIA; INSOMNIA; LUNG CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT SATISFACTION; REPEATED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TESTIS CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT GAIN;

EID: 54749098776     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400401     Document Type: Review

References (27)

1. Sharma R, Tobin P, Clarke SJ: Management of chemotherapy-induced nausea, vomiting, oral mucositis, diarrhea. Lancet Oncol, 6: 93-102, 2005.
2. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G: Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer, 100: 2261-2268, 2004.
3. Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer, 8: 229-232, 1999.
4. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ: A meta-analysis comparing of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 15: 1023-1033, 2007.
5. Grunberg SM: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol, 18: 233-240, 2007.
6. Geling O, Eichler HG: Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic reevaluation of clinical evidence and drug cost implications. J Clin Oncol, 23: 1289-1294, 2005.
7. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J: Delayed nausea and vomiting continue to reduce patient's quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol, 24: 4472-4478, 2006.
8. Aapro M: 5-HT(3)-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology, 69: 97-109, 2005.
9. Rojas C, Stathis M, Alt J, Rubenstein E, Cantoreggi S, Sebastiani S, Slusher B: Additional binding mechanism of palonosetron to the 5-HT3 receptor versus first generation 5-HT3 receptor antagonists. J Clin Oncol, 25: (Abstract 19583), 2007. Available at http://www.asco.org; accessed October 23, 2007.
10. Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol, 14: 1570-1577, 2003.
11. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S: Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor anatagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer, 98: 2473-2482, 2003.
12. Aapro M, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 17: 1441-1449, 2006.
13. Decker GM, DeMeyer ES, Kisko DL: Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol, 4: 35-41, 2006.
14. Grunberg SM, Vanden Burgt JA, Berry S, Rubenstein EB, Berry D: Prevention of delayed nausea and vomiting (D-CINV): carryover effect analysis of pooled data from 2 phase III studies of palonosetron (PALO). Proc Am Soc Clin Oncol, 23: 738 (Abstract 8051), 2004.
15. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM: American Society of Clinical Oncology guidelines for antiemetics in oncology: update 2006. J Clin Oncol, 24: 2932-2947, 2006.
16. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Antiemesis, version 1.2007. Available at http://www.nccn.org; accessed September 18, 2007.
17. Hardenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA: Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Support Oncol, 4: 467-471, 2006.
18. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V: Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J Support Oncol, 4: 403-408, 2006.
19. Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS: A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer, 15: 1285-1291, 2007.
20. Rubenstein EB, Gralla RJ, Eisenberg P, Sleeboom O, Vtoraya A, Macciocchi A, Olivares G, Berry D: Palonosetron (PALO) compared with ondansetron (OND) or dalasetron (DOL) for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV): combined results of two phase III trials. Proc Am Soc Clin Oncol, 22: 729 (Abstract 2932), 2003.
21. Roila F, Fatigoni S: New antiemetic drugs. Ann Oncol, 17 (Suppl 2): ii96-ii100, 2006.
22. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94: 1011-1015, 2006.
23. Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W: A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer, 13: 529-534, 2005.
24. Hunt TL, Gallagher SC, Cullen MT Jr, Shah AK: Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J Clin Pharmacol, 45: 589-596, 2005.
25. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J: Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer, 15: 1293-1300, 2007.
26. Baltzer L, Pisters KMW, Kris MG, Tyson LB, Potanovich LM, Rigas JR, Bajorin DF, Motzer RJ, Pfister DG, Bosl GJ: High-dose ondansetron (OND) plus dexamethasone (DEX) for the prevention of nausea and vomiting with multiple-day cisplatin chemotherapy. Proc Am Soc Clin Oncol, 12: 462 (Abstract 1607), 1993.
27. Fox SM, Einhorn LH, Cox E, Powell E, Abdy A: Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol, 11: 2391-2395, 1993.